North America Persistent Corneal Epithelial Defects Treatment Market - Industry Trends and Forecast to 2027

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW

4.1 DRIVERS

4.1.1 INCREASING PREVALENCE OF PERSISTENT CORNEAL EPITHELIAL DEFECTS AND OTHER RELATED COMPLICATIONS

4.1.2 RISING CASES OF EYE SURGERIES AND USAGE OF CONTACT LENSES

4.1.3 GROWING AGEING POPULATION AUGMENTING TOWARDS THE PCED CONDITION

4.1.4 INCREASE IN MECHANICAL TRAUMAS CASES

4.2 RESTRAINT

4.2.1 STRINGENT REGULATORY PROCEDURES

4.2.2 UNMET MEDICAL NEEDS FOR THE TREATMENT OF PCED

4.2.3 HIGH COST OF PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENTS

4.3 OPPORTUNITIES

4.3.1 DEVELOPMENT OF NOVEL THERAPEUTICS

4.3.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE

4.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

4.3.4 EMERGING MARKET ECONOMY CREATES SIGNIFICANT OPPORTUNITIES

4.4 CHALLENGES

4.4.1 DEPENDENCY ON THIRD PARTY SUPPLIERS

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY

7 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES

7.1 OVERVIEW

7.2 INFLAMMATORY DISEASE

7.3 NEUROTROPHIC KERATITIS (NK)

7.4 EPITHELIAL/LIMBAL STEM CELL DEFICIENCY

7.5 OTHERS

8 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 DEVICES

8.2.1 BANDAGE CONTACT LENS

8.2.2 AMNIOTIC MEMBRANE GRAFTS

8.2.3 PUNCTAL PLUGS

8.2.3.1 SILICONE PLUG

8.2.3.2 COLLAGEN PLUGS

8.2.4 CORNEAL TRANSPLANTS

8.2.4.1 KERATOPLASTY

8.2.4.2 KERATOPROSTHESIS

8.3 MEDICATION

8.3.1 DRUG TYPE

8.3.1.1 LUBRICANTS

8.3.1.2 PROPHYLACTIC TOPICAL ANTIBIOTICS

8.3.1.2.1 POLYMIXIN B–TRIMETHOPRIM + FLUOROQUINOLONE

8.3.1.2.2 FLUOROQUINOLONE

8.3.1.3 TOPICAL OPHTHALMIC STEROIDS

8.3.1.4 AUTOLOGOUS SERUM TEARS/AUTOLOGOUS SERUM EYE DROPS

8.3.1.5 TETRACYCLINES

8.3.1.6 HUMAN NERVE GROWTH FACTOR (OXERVATE)

8.3.1.7 WOUND HEALING AGENTS

8.3.1.8 OTHERS

8.3.2 ROUTE OF ADMINISTRATION

8.3.2.1 TOPICAL

8.3.2.2 ORAL

9 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 HOMECARE

9.4 SPECIALTY CLINICS

9.5 OTHERS

10 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACIES

10.3 RETAIL PHARMACIES

10.4 ONLINE PHARMACIES

11 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY GEOGRAPHY

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 COMPANY PROFILE

13.1 JOHNSON & JOHNSON SERVICES, INC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 ALLERGAN

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 COMPANY SHARE ANALYSIS

13.2.4 PRODUCT PORTFOLIO

13.2.5 RECENT DEVELOPMENT

13.3 BIO-TISSUE (A SUBSIDIARY OF TISSUETECH, INC.)

13.3.1 COMPANY SNAPSHOT

13.3.2 COMPANY SHARE ANALYSIS

13.3.3 PRODUCT PORTFOLIO

13.3.4 RECENT DEVELOPMENTS

13.4 LABORATOIRES THÉA S.A.S

13.4.1 COMPANY SNAPSHOT

13.4.2 COMPANY SHARE ANALYSIS

13.4.3 PRODUCT PORTFOLIO

13.4.4 RECENT DEVELOPMENT

13.5 NOVARTIS AG

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENT

13.6 BAUSCH HEALTH

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENT

13.7 INTEGRA LIFESCIENCES CORPORATION

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENT

13.8 ALMIRALL, S.A

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENT

13.9 DOMPÉ FARMACEUTICI S.P.A.

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENTS

13.10 HUNT VALLEY PHARMALAB

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENT

13.11 I-MED PHARMA INC.

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENT

13.12 KALA PHARMACEUTICALS

13.12.1 COMPANY SNAPSHOT

13.12.2 PRODUCT PORTFOLIO

13.12.3 RECENT DEVELOPMENTS

13.13 KATENA PRODUCTS. INC.

13.13.1 COMPANY SNAPSHOT

13.13.2 PRODUCT PORTFOLIO

13.13.3 RECENT DEVELOPMENTS

13.14 NEXT BIOSCIENCES

13.14.1 COMPANY SNAPSHOT

13.14.2 PRODUCT PORTFOLIO

13.14.3 RECENT DEVELOPMENT

13.15 OCULAR SCIENCE, INC.

13.15.1 COMPANY SNAPSHOT

13.15.2 PRODUCT PORTFOLIO

13.15.3 RECENT DEVELOPMENT

13.16 SKYE BIOLOGICS INC.

13.16.1 COMPANY SNAPSHOT

13.16.2 PRODUCT PORTFOLIO

13.16.3 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS

UU

TABLE 1 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 2 NORTH AMERICA INFLAMMATORY DISEASE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 NORTH AMERICA NEUROTROPHIC KERATITIS (NK) IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 NORTH AMERICA EPITHELIAL/LIMBAL STEM CELL DEFICIENCY IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 NORTH AMERICA OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 7 NORTH AMERICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 NORTH AMERICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 NORTH AMERICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 10 NORTH AMERICA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 NORTH AMERICA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 12 NORTH AMERICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 13 NORTH AMERICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 14 NORTH AMERICA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 15 NORTH AMERICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 16 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 17 NORTH AMERICA HOSPITALS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 18 NORTH AMERICA HOMECARE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 NORTH AMERICA SPECIALTY CLINICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 NORTH AMERICA OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 22 NORTH AMERICA HOSPITAL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 23 NORTH AMERICA RETAIL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 NORTH AMERICA ONLINE PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 25 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 26 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 27 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 28 NORTH AMERICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 29 NORTH AMERICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 30 NORTH AMERICA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 31 NORTH AMERICA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 32 NORTH AMERICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 33 NORTH AMERICA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 34 NORTH AMERICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 36 NORTH AMERICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 37 U.S. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 38 U.S. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 39 U.S. DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 40 U.S. DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 41 U.S. PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 42 U.S. CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 43 U.S. MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 44 U.S. PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 45 U.S. MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 46 U.S. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 U.S. PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 48 CANADA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 49 CANADA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 CANADA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 CANADA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 52 CANADA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 53 CANADA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 54 CANADA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 55 CANADA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 CANADA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 57 CANADA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 CANADA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 59 MEXICO PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 60 MEXICO PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 MEXICO DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 MEXICO DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 63 MEXICO PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 MEXICO CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 MEXICO MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 66 MEXICO PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 67 MEXICO MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 68 MEXICO PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 69 MEXICO PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)